Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26115582 | 0.98 | CTSC (0.46) | CTSCCYP2D6CYP1A2ALOX15CYP2C19 | |
| SCHEMBL4868082 | 0.83 | CYP2D6 (0.42) | CTSCCYP2D6CYP1A2ALOX15CYP2C19 | |
| Hydrochloric Acid SCHEMBL30572004 | 0.80 | CTSC (0.44) | CTSCDNMT1 | |
| SCHEMBL6335294 | 0.79 | ALOX15 (0.39) | CTSCCYP2D6CYP1A2ALOX15CYP2C19 | |
| SCHEMBL6329716 | 0.79 | ALOX15 (0.39) | CTSCCYP2D6CYP1A2ALOX15CYP2C19 | |
| SCHEMBL7306083 | 0.79 | CYP2D6 (0.52) | CTSCCYP2D6CYP1A2ALOX15CYP2C19 | |
| SCHEMBL7340749 | 0.79 | CYP2D6 (0.52) | CTSCCYP2D6CYP1A2ALOX15CYP2C19 | |
| SCHEMBL6329133 | 0.79 | CYP2D6 (0.52) | CTSCCYP2D6CYP1A2ALOX15CYP2C19 | |
| SCHEMBL7873903 | 0.79 | CYP2D6 (0.52) | CTSCCYP2D6CYP1A2ALOX15CYP2C19 | |
| SCHEMBL7340833 | 0.79 | CYP2D6 (0.52) | CTSCCYP2D6CYP1A2ALOX15CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007516172-A | — | — | 2007-06-21 | — | — | JP | claimed |
| US-7199106-B2 | Lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | claimed |
| EP-1644393-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | claimed |
| WO-2005012320-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | claimed |
| US-7361743-B2 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PFIZER INC (US) | 2008-04-22 | — | — | US | disclosed |
| US-7256177-B2 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| EP-1814893-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7199106-B2 | Lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-07-06 | — | — | US | disclosed |
| WO-2006055070-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| EP-1644393-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | VICURON PHARMACEUTICALS INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | VICURON PHARMACEUTICALS INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005012320-A2 | NOVEL LINCOMYCIN DERIVATIVES POSSESSING ANTIMICROBIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148722-A1 | Novel lincomycin derivatives possessing antibacterial activity | LCLAT1, LAS1L, NRDC | CTSC 1047/4885CYP2D6 2712/4885CYP1A2 3996/4885 |
| US-20050215488-A1 | Such as 5-propyl-azepane-2-carboxylic acid [2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydro-pyran-2-yl)-propyl]-amide; for prevention and treatment of mycobacterial, mycoplasmal or chlamydia infection; microbiocides | PAM, MLYCD, PPT1 | CTSC 684/4885CYP2D6 2097/4885CYP1A2 3444/4885 |
| US-20050043248-A1 | Novel lincomycin derivatives possessing antimicrobial activity | LCLAT1, NRDC, LAS1L | CTSC 962/4885CYP2D6 2845/4885CYP1A2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.